A dendritic cell (DC)-based therapeutic vaccination was evaluated in a phase I/II clinical immunotherapy trial in which seventeen HIV-1 infected patients on cART received autologous DCs electroporated with mRNA encoding HIV-1 Tat, Rev, and Nef (DC-TRN) before analytical treatment interruption. The trial provided a unique longitudinal set comprising samples from up to seven years prior administration of immunotherapy, at time of cART initiation and up to two-years post-vaccination. To determine the potential effects of DC vaccination on viral evolution and CD8+ T-cell epitope regions, pre- and post-vaccination sequences of whole genes within and outside tat, rev, and nef were obtained from plasma RNA before initiation of cART and after vaccination during viral load rebound following analytical treatment interruption. Control sequences for virus evolution in untreated HIV-1-infected individuals were obtained from the LANL HIV Sequence Database. The first set of data was obtained with Sanger sequencing, which revealed that viral sequence evolution in the tat, rev, and nef genes of vaccinated patients was similar to that of controls. Furthermore, the number of mutations observed inside and outside CD8+ T-cell epitopes was comparable for vaccine-targeted and non-targeted proteins, although occasional escape from CTL pressure was observed. Based on consensus sequence analysis, no evidence for a widespread impact of vaccine-induced or enhanced immune responses on the number of mutations inside or outside epitopes was found. Subsequently, whole-genome NGS on plasma samples from the same patients and time points as that for Sanger sequencing was performed. An in depth analysis of the NGS data to characterize virus evolution in tat, rev, and nef versus the rest of the genome is still lacking. Further analysis is required to search for minor variants that mutate under CTL pressure. These results may guide further research on plasma as well as PBMC samples that are still available.
